Pilot clinical trial to evaluate the efficacy, safety and tolerability of switching to treatment with Bictegravir/FTC/TAF (Biktarvy®) plus darunavir/cobicistat in heavily treated HIV-1 infected patients.
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: RIS ASSOCIATION (AIDS RESEARCH NETWORK)
- Phase: IV
- Execution start: 21/01/2021
- End of execution: 30/04/2022
- PI: CARMEN HIDALGO TENORIO